Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
Titel:
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
Auteur:
Pivot, X. Verma, S. Fallowfield, L. Müller, V. Lichinitser, M. Jenkins, V. Sánchez Muñoz, A. Machackova, Z. Osborne, S. Gligorov, J.